Pharmacogenetics of Antidepressant-Induced Disinhibition
Condition(s) studied
Study summary
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Eligibility
Primary outcome measure(s)
- Genetic variants in SSRI metabolism — 4 years
DNA Sample Collection \& Genotyping. Saliva will be collected using Oragene® collection tubes (DNA Genotek, Ottawa, Canada). DNA will be extracted using standard procedures and genotyped. - Behavioural Disinhibition — 4 years
Information on behavioural disinhibition (BD) to note the type, duration and severity of BD gathered from medical records, and participant and parent report. The Treatment-emergent activation and suicidality assessment profile (TEASAP), is a questionnaire that assess common symptoms of activation syndrome/behavioural disinhibition in youth due to SSRI usage.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Child and Adolescent Addiction, Mental Health & Psychiatry | Calgary | Alberta | Recruiting |
More University of Calgary trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03953014 on ClinicalTrials.gov ↗ ← All trials in Canada